Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-02

AUTHORS

Akiko Chiba, Tanya L. Hoskin, Courtney N. Heins, Kelly K. Hunt, Elizabeth B. Habermann, Judy C. Boughey

ABSTRACT

BACKGROUND: The American College of Surgeons Oncology Group Z1031 trial demonstrated that neoadjuvant endocrine therapy (NET) increased breast-conserving surgery (BCS) rates for postmenopausal patients with clinical tumor stage 2-4c estrogen receptor-positive breast cancer. We evaluated national trends in NET use in relation to the conduct of the Z1031 trial and the impact of NET on the rates of BCS. METHODS: Using the National Cancer Data Base (NCDB), we identified all cT2-4c hormone receptor (HR)-positive breast cancer patients age ≥50 years from 2004 to 2012. The time intervals of pre-Z1031 (2004-2006), during Z1031 (2007-2009), and post-Z1031 (2010-2012) were examined, and adjusted analyses were performed using multivariable logistic regression. RESULTS: Of 77,272 patients, 2294 (3.0 %) received NET. Clinical T-stage distribution was 66,885 (86.6 %) for cT2, 7318 (9.5 %) for cT3, and 3069 (4.0 %) for cT4a-c. A small but statistically significant increase in NET use was noted, from 2.7 % pre-Z1031 to 3.2 % post-Z1031; the adjusted odds ratio (OR) for NET was 1.28 [95 % confidence interval (CI) 1.13-1.45; p < 0.001] for post-Z1031 versus pre-Z1031. NET use varied by clinical T stage, increasing from 1.8 % pre-Z1031 to 2.4 % post-Z1031 in cT2 patients (p < 0.001) and from 6.3 % pre-Z1031 to 7.4 % post-Z1031 in cT3 patients (p = 0.02). Patients receiving NET were more likely to undergo BCS compared with patients undergoing primary surgery (46.4 vs. 43.9 %; p = 0.02) with an adjusted OR of 1.60 (95 % CI 1.46-1.75; p < 0.001). CONCLUSIONS: NET use has increased slowly since the Z1031 trial; however, overall use remains low. NET significantly increased the rates of BCS in patients with HR-positive clinical T2-4c breast cancer. Clinicians should consider NET use for patients with HR-positive breast cancer interested in BCS. More... »

PAGES

418-424

Identifiers

URI

http://scigraph.springernature.com/pub.10.1245/s10434-016-5585-5

DOI

http://dx.doi.org/10.1245/s10434-016-5585-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1039667624

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27663568


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aromatase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Databases, Factual", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mastectomy, Segmental", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoadjuvant Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Postmenopause", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Mayo Clinic", 
          "id": "https://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Department of Surgery, Mayo Clinic, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chiba", 
        "givenName": "Akiko", 
        "id": "sg:person.013237654075.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013237654075.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mayo Clinic", 
          "id": "https://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hoskin", 
        "givenName": "Tanya L.", 
        "id": "sg:person.01234406572.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234406572.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mayo Clinic", 
          "id": "https://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heins", 
        "givenName": "Courtney N.", 
        "id": "sg:person.01346302553.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346302553.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Alliance for Clinical Trials in Oncology", 
          "id": "https://www.grid.ac/institutes/grid.468206.e", 
          "name": [
            "Department of Breast Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA", 
            "American College of Surgeons Clinical Research Program and Alliance for Clinical Trials in Oncology, Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hunt", 
        "givenName": "Kelly K.", 
        "id": "sg:person.01340214713.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340214713.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mayo Clinic", 
          "id": "https://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Department of Surgery, Mayo Clinic, Rochester, MN, USA", 
            "Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA", 
            "Robert D. and Patricia E. Kern Center for Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Habermann", 
        "givenName": "Elizabeth B.", 
        "id": "sg:person.0675762300.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675762300.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Alliance for Clinical Trials in Oncology", 
          "id": "https://www.grid.ac/institutes/grid.468206.e", 
          "name": [
            "Department of Surgery, Mayo Clinic, Rochester, MN, USA", 
            "American College of Surgeons Clinical Research Program and Alliance for Clinical Trials in Oncology, Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boughey", 
        "givenName": "Judy C.", 
        "id": "sg:person.01002630265.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002630265.04"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2005.04.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000047665"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.04.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000047665"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-008-0223-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009332631", 
          "https://doi.org/10.1007/s10549-008-0223-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-008-0223-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009332631", 
          "https://doi.org/10.1007/s10549-008-0223-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-011-2108-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011255060", 
          "https://doi.org/10.1245/s10434-011-2108-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/94.14.1054", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014709051"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.31.6950", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019109042"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.breast.2005.07.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042446272"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.breast.2005.07.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042446272"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdp322", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042592360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdp322", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042592360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2012.07.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045514575"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1013128213451", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056306132"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.5.1474", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074460868"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.18.3808", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074881995"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-02", 
    "datePublishedReg": "2017-02-01", 
    "description": "BACKGROUND: The American College of Surgeons Oncology Group Z1031 trial demonstrated that neoadjuvant endocrine therapy (NET) increased breast-conserving surgery (BCS) rates for postmenopausal patients with clinical tumor stage 2-4c estrogen receptor-positive breast cancer. We evaluated national trends in NET use in relation to the conduct of the Z1031 trial and the impact of NET on the rates of BCS.\nMETHODS: Using the National Cancer Data Base\u00a0(NCDB), we identified all cT2-4c hormone receptor (HR)-positive breast cancer patients age \u226550\u00a0years from 2004 to 2012. The time intervals of pre-Z1031 (2004-2006), during Z1031 (2007-2009), and post-Z1031 (2010-2012) were examined, and adjusted analyses were performed using multivariable logistic regression.\nRESULTS: Of 77,272 patients, 2294 (3.0\u00a0%) received NET. Clinical T-stage distribution was 66,885 (86.6\u00a0%) for cT2, 7318 (9.5\u00a0%) for cT3, and 3069 (4.0\u00a0%) for cT4a-c. A small but statistically significant increase in NET use was noted, from 2.7\u00a0% pre-Z1031 to 3.2\u00a0% post-Z1031; the adjusted odds ratio (OR) for NET was 1.28 [95\u00a0% confidence interval (CI) 1.13-1.45; p\u00a0<\u00a00.001] for post-Z1031 versus pre-Z1031. NET use varied by clinical T stage, increasing from 1.8\u00a0% pre-Z1031 to 2.4\u00a0% post-Z1031 in cT2 patients (p\u00a0<\u00a00.001) and from 6.3\u00a0% pre-Z1031 to 7.4\u00a0% post-Z1031 in cT3 patients (p\u00a0=\u00a00.02). Patients receiving NET were more likely to undergo BCS compared with patients undergoing primary surgery (46.4 vs. 43.9\u00a0%; p\u00a0=\u00a00.02) with an adjusted OR of 1.60 (95\u00a0% CI 1.46-1.75; p\u00a0<\u00a00.001).\nCONCLUSIONS: NET use has increased slowly since the Z1031 trial; however, overall use remains low. NET significantly increased the rates of BCS in patients with HR-positive clinical T2-4c breast cancer. Clinicians should consider NET use for patients with HR-positive breast cancer interested in BCS.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1245/s10434-016-5585-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.3535792", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1105545", 
        "issn": [
          "1068-9265", 
          "1534-4681"
        ], 
        "name": "Annals of Surgical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "name": "Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study", 
    "pagination": "418-424", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "bcf57c025a0529802dc0a8617f1b0cf32e54d3086cce127589bd380d2c3199d7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27663568"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9420840"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1245/s10434-016-5585-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1039667624"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1245/s10434-016-5585-5", 
      "https://app.dimensions.ai/details/publication/pub.1039667624"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000363_0000000363/records_70049_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1245%2Fs10434-016-5585-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1245/s10434-016-5585-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1245/s10434-016-5585-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1245/s10434-016-5585-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1245/s10434-016-5585-5'


 

This table displays all metadata directly associated to this object as RDF triples.

204 TRIPLES      21 PREDICATES      54 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1245/s10434-016-5585-5 schema:about N362f600483514bb9843aa52fcdc185bf
2 N526a3a719c684ca5858c1d7614105298
3 N74b472f6593447ee8ba746183588a999
4 N75cdaeae5576498b8b99d00eaf23b854
5 N8f39ee18a6284287b78d9bcbad356cc9
6 N8facfc4e65114e068af39334814864a8
7 N946ee98406c54eb8874dffc9edaa4a7f
8 N9b859dc608c44b518ce2cf85275ef01e
9 Na08a579923fb437fbb75ed83e7708af6
10 Nab57cf38e6b8428f94ca88203121e73e
11 Nae25dda8ab9544629c418b3c3ca138e3
12 Ndf07166a0b734b7fa9a1fe0bb29898d8
13 Ne5a965de28804415b3fead8f169d3bfa
14 Nfad8900fbad54629bdb0b59f51219081
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author Nc745b78fc29745128a6fab5d9b83d8cd
18 schema:citation sg:pub.10.1007/s10549-008-0223-y
19 sg:pub.10.1245/s10434-011-2108-2
20 https://doi.org/10.1016/j.breast.2005.07.009
21 https://doi.org/10.1016/j.ejca.2012.07.026
22 https://doi.org/10.1023/a:1013128213451
23 https://doi.org/10.1093/annonc/mdp322
24 https://doi.org/10.1093/jnci/94.14.1054
25 https://doi.org/10.1200/jco.1999.17.5.1474
26 https://doi.org/10.1200/jco.2001.19.18.3808
27 https://doi.org/10.1200/jco.2005.04.005
28 https://doi.org/10.1200/jco.2010.31.6950
29 schema:datePublished 2017-02
30 schema:datePublishedReg 2017-02-01
31 schema:description BACKGROUND: The American College of Surgeons Oncology Group Z1031 trial demonstrated that neoadjuvant endocrine therapy (NET) increased breast-conserving surgery (BCS) rates for postmenopausal patients with clinical tumor stage 2-4c estrogen receptor-positive breast cancer. We evaluated national trends in NET use in relation to the conduct of the Z1031 trial and the impact of NET on the rates of BCS. METHODS: Using the National Cancer Data Base (NCDB), we identified all cT2-4c hormone receptor (HR)-positive breast cancer patients age ≥50 years from 2004 to 2012. The time intervals of pre-Z1031 (2004-2006), during Z1031 (2007-2009), and post-Z1031 (2010-2012) were examined, and adjusted analyses were performed using multivariable logistic regression. RESULTS: Of 77,272 patients, 2294 (3.0 %) received NET. Clinical T-stage distribution was 66,885 (86.6 %) for cT2, 7318 (9.5 %) for cT3, and 3069 (4.0 %) for cT4a-c. A small but statistically significant increase in NET use was noted, from 2.7 % pre-Z1031 to 3.2 % post-Z1031; the adjusted odds ratio (OR) for NET was 1.28 [95 % confidence interval (CI) 1.13-1.45; p < 0.001] for post-Z1031 versus pre-Z1031. NET use varied by clinical T stage, increasing from 1.8 % pre-Z1031 to 2.4 % post-Z1031 in cT2 patients (p < 0.001) and from 6.3 % pre-Z1031 to 7.4 % post-Z1031 in cT3 patients (p = 0.02). Patients receiving NET were more likely to undergo BCS compared with patients undergoing primary surgery (46.4 vs. 43.9 %; p = 0.02) with an adjusted OR of 1.60 (95 % CI 1.46-1.75; p < 0.001). CONCLUSIONS: NET use has increased slowly since the Z1031 trial; however, overall use remains low. NET significantly increased the rates of BCS in patients with HR-positive clinical T2-4c breast cancer. Clinicians should consider NET use for patients with HR-positive breast cancer interested in BCS.
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree true
35 schema:isPartOf N6903af16903c4c609a2c2ebff90993b0
36 N76a11256e5b84623ba16d12acb972dcf
37 sg:journal.1105545
38 schema:name Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study
39 schema:pagination 418-424
40 schema:productId N053e78571b64431089fadf379656b587
41 N982c69b1ec6b4dc7b2314ad056601cc3
42 Nc1e11e0d6bc542b490af2ed2c3c5771b
43 Nd310c342b8ad43daa0271d253a5ffab7
44 Ne0973f37bf774772b4bf8b17faa5475d
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039667624
46 https://doi.org/10.1245/s10434-016-5585-5
47 schema:sdDatePublished 2019-04-11T12:40
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher N3e82f18ac5de46539de70834d8a12ff3
50 schema:url https://link.springer.com/10.1245%2Fs10434-016-5585-5
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N053e78571b64431089fadf379656b587 schema:name readcube_id
55 schema:value bcf57c025a0529802dc0a8617f1b0cf32e54d3086cce127589bd380d2c3199d7
56 rdf:type schema:PropertyValue
57 N362f600483514bb9843aa52fcdc185bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name Aged
59 rdf:type schema:DefinedTerm
60 N3e2dd6f61e5b4eaebc80ecc91e219acf rdf:first sg:person.01234406572.36
61 rdf:rest Ncc4f58ee34964259997b27a62981ece7
62 N3e82f18ac5de46539de70834d8a12ff3 schema:name Springer Nature - SN SciGraph project
63 rdf:type schema:Organization
64 N526a3a719c684ca5858c1d7614105298 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Aged, 80 and over
66 rdf:type schema:DefinedTerm
67 N6903af16903c4c609a2c2ebff90993b0 schema:volumeNumber 24
68 rdf:type schema:PublicationVolume
69 N74b472f6593447ee8ba746183588a999 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Databases, Factual
71 rdf:type schema:DefinedTerm
72 N75cdaeae5576498b8b99d00eaf23b854 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Mastectomy, Segmental
74 rdf:type schema:DefinedTerm
75 N76a11256e5b84623ba16d12acb972dcf schema:issueNumber 2
76 rdf:type schema:PublicationIssue
77 N8f39ee18a6284287b78d9bcbad356cc9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Humans
79 rdf:type schema:DefinedTerm
80 N8facfc4e65114e068af39334814864a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Follow-Up Studies
82 rdf:type schema:DefinedTerm
83 N946ee98406c54eb8874dffc9edaa4a7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Breast Neoplasms
85 rdf:type schema:DefinedTerm
86 N982c69b1ec6b4dc7b2314ad056601cc3 schema:name doi
87 schema:value 10.1245/s10434-016-5585-5
88 rdf:type schema:PropertyValue
89 N9b859dc608c44b518ce2cf85275ef01e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Survival Rate
91 rdf:type schema:DefinedTerm
92 N9df2cd1df3614d4ebb7f8fbf711fa250 rdf:first sg:person.01340214713.66
93 rdf:rest Ndc192650671440118acc1771258b4f9f
94 Na08a579923fb437fbb75ed83e7708af6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Postmenopause
96 rdf:type schema:DefinedTerm
97 Nab57cf38e6b8428f94ca88203121e73e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Neoadjuvant Therapy
99 rdf:type schema:DefinedTerm
100 Nae25dda8ab9544629c418b3c3ca138e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Prognosis
102 rdf:type schema:DefinedTerm
103 Nbaa684f9581e4211bf697ea5c0b94ea5 rdf:first sg:person.01002630265.04
104 rdf:rest rdf:nil
105 Nc1e11e0d6bc542b490af2ed2c3c5771b schema:name pubmed_id
106 schema:value 27663568
107 rdf:type schema:PropertyValue
108 Nc745b78fc29745128a6fab5d9b83d8cd rdf:first sg:person.013237654075.35
109 rdf:rest N3e2dd6f61e5b4eaebc80ecc91e219acf
110 Ncc4f58ee34964259997b27a62981ece7 rdf:first sg:person.01346302553.97
111 rdf:rest N9df2cd1df3614d4ebb7f8fbf711fa250
112 Nd310c342b8ad43daa0271d253a5ffab7 schema:name nlm_unique_id
113 schema:value 9420840
114 rdf:type schema:PropertyValue
115 Ndc192650671440118acc1771258b4f9f rdf:first sg:person.0675762300.99
116 rdf:rest Nbaa684f9581e4211bf697ea5c0b94ea5
117 Ndf07166a0b734b7fa9a1fe0bb29898d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Middle Aged
119 rdf:type schema:DefinedTerm
120 Ne0973f37bf774772b4bf8b17faa5475d schema:name dimensions_id
121 schema:value pub.1039667624
122 rdf:type schema:PropertyValue
123 Ne5a965de28804415b3fead8f169d3bfa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Female
125 rdf:type schema:DefinedTerm
126 Nfad8900fbad54629bdb0b59f51219081 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Aromatase Inhibitors
128 rdf:type schema:DefinedTerm
129 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
130 schema:name Medical and Health Sciences
131 rdf:type schema:DefinedTerm
132 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
133 schema:name Oncology and Carcinogenesis
134 rdf:type schema:DefinedTerm
135 sg:grant.3535792 http://pending.schema.org/fundedItem sg:pub.10.1245/s10434-016-5585-5
136 rdf:type schema:MonetaryGrant
137 sg:journal.1105545 schema:issn 1068-9265
138 1534-4681
139 schema:name Annals of Surgical Oncology
140 rdf:type schema:Periodical
141 sg:person.01002630265.04 schema:affiliation https://www.grid.ac/institutes/grid.468206.e
142 schema:familyName Boughey
143 schema:givenName Judy C.
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002630265.04
145 rdf:type schema:Person
146 sg:person.01234406572.36 schema:affiliation https://www.grid.ac/institutes/grid.66875.3a
147 schema:familyName Hoskin
148 schema:givenName Tanya L.
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234406572.36
150 rdf:type schema:Person
151 sg:person.013237654075.35 schema:affiliation https://www.grid.ac/institutes/grid.66875.3a
152 schema:familyName Chiba
153 schema:givenName Akiko
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013237654075.35
155 rdf:type schema:Person
156 sg:person.01340214713.66 schema:affiliation https://www.grid.ac/institutes/grid.468206.e
157 schema:familyName Hunt
158 schema:givenName Kelly K.
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340214713.66
160 rdf:type schema:Person
161 sg:person.01346302553.97 schema:affiliation https://www.grid.ac/institutes/grid.66875.3a
162 schema:familyName Heins
163 schema:givenName Courtney N.
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346302553.97
165 rdf:type schema:Person
166 sg:person.0675762300.99 schema:affiliation https://www.grid.ac/institutes/grid.66875.3a
167 schema:familyName Habermann
168 schema:givenName Elizabeth B.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675762300.99
170 rdf:type schema:Person
171 sg:pub.10.1007/s10549-008-0223-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1009332631
172 https://doi.org/10.1007/s10549-008-0223-y
173 rdf:type schema:CreativeWork
174 sg:pub.10.1245/s10434-011-2108-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011255060
175 https://doi.org/10.1245/s10434-011-2108-2
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1016/j.breast.2005.07.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042446272
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1016/j.ejca.2012.07.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045514575
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1023/a:1013128213451 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056306132
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1093/annonc/mdp322 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042592360
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1093/jnci/94.14.1054 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014709051
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1200/jco.1999.17.5.1474 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074460868
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1200/jco.2001.19.18.3808 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074881995
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1200/jco.2005.04.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000047665
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1200/jco.2010.31.6950 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019109042
194 rdf:type schema:CreativeWork
195 https://www.grid.ac/institutes/grid.468206.e schema:alternateName Alliance for Clinical Trials in Oncology
196 schema:name American College of Surgeons Clinical Research Program and Alliance for Clinical Trials in Oncology, Chicago, IL, USA
197 Department of Breast Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA
198 Department of Surgery, Mayo Clinic, Rochester, MN, USA
199 rdf:type schema:Organization
200 https://www.grid.ac/institutes/grid.66875.3a schema:alternateName Mayo Clinic
201 schema:name Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
202 Department of Surgery, Mayo Clinic, Rochester, MN, USA
203 Robert D. and Patricia E. Kern Center for Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA
204 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...